Jc. Moller et al., SURFACTANT TREATMENT IN CHILDREN WITH ACQ UIRED RESPIRATORY-DISTRESS SYNDROME, Monatsschrift fur Kinderheilkunde, 143(7), 1995, pp. 685-690
Background and Methods: Exogenous surfactant has been proven to be a v
ery effective treatment in neonatal RDS. Also in ARDS it is a promisin
g option since it can open nonventilated lung areas. ARDS therapy in p
ediatric patients includes modifications of ventilation, permissive hy
percapnia, high frequency ventilation, intratracheal ventilation, and
finally ECMO. We treated children (age 1-32 months) transferred for EC
MO with exogenous surfactant. This therapy was integrated into an algo
rithm, including vasodilatation in cases of proven pulmonary hypertens
ion, in a tied time frame allowing ECMO as a definite therapy (table 1
). 6 patients were treated as their FiO(2), was > 0.8 and their mean a
irway pressure > 20 mmHg for more than 48 hrs., not responsive to conv
entional ventilation strategies and hemodynamic stabilization. They go
t 40-380mg/kg bovine surfactant (Alveofact (R), Thomae, Biberach/Germa
ny) in to 3 doses over 15 min each time through a special adapter (Alv
eodapter) under continuous ventilatory support. OI and AaDO(2) were me
asured at 1, 4, 24, 48, 72hrs. and at discharge. At the same times MOD
S was scored as was the chest x-ray (20, 21). Results: OI and AaDO(2)
decreased significantly (p < 0.01) from a mean 50.2 (+/- 29.9 SD) to 2
5.7 (+/- 17 SD) and 577 (+/- 46 SD) to 413 (+/- 148 SD) in one hour. T
his decrease was unchanged until discharge or discontinuation of life
support in 2 patients because of severe cerebral damage. In one patien
t doses of surfactant of 240 mg/kg twice did not improve OI and AaDO(2
), he died despite ECMO-therapy. Conclusions: Exogenous surfactant is
an effective therapy in pediatric ARDS patients with predominantly par
enchymal disease and severe ventilation/perfusion mismatch. Especially
for the transport of these patients to an ECMO center it is an instan
taneously available, easily applicable therapy. Its value in treatment
-algorithms for pediatric ARDS has to be determined in internationally
centralized information networks.